TY - JOUR
T1 - Light-activated gene transduction of recombinant adeno-associated virus in human mesenchymal stem cells
AU - Ito, H.
AU - Goater, J. J.
AU - Tiyapatanaputi, P.
AU - Rubery, P. T.
AU - O'Keefe, R. J.
AU - Schwarz, E. M.
N1 - Funding Information:
This work was supported by grants from the National Institutes of Health (PHS AR45791 and AR44220) and an unrestricted educational grant from DePuy AcroMed Inc. JJG, PTR, RJO and EMS are founders of LAGeT Inc.
PY - 2004/1
Y1 - 2004/1
N2 - Deficiencies in skeletal tissue repair and regeneration lead to conditions like osteoarthritis, osteoporosis and degenerative disc disease. While no cure for these conditions is available, the use of human bone marrow derived-mesenchymal stem cells (HuMSCs) has been shown to have potential for cell-based therapy. Furthermore, recombinant adeno-associated viruses (rAAV) could be used together with HuMSCs for in vivo or ex vivo gene therapy. Unfortunately, the poor transduction efficiency of these cells remains a significant obstacle. Here, we describe the properties of ultraviolet (UV) light-activated gene transduction (LAGT) with rAAV in HuMSCs, an advance toward overcoming this limitation. Using direct fluorescent image analysis and real-time quantitative PCR to evaluate enhanced green fluorescent protein (eGFP) gene expression, we found that the optimal effects of LAGT with limited cytotoxicity occurred at a UV dose of 200 J/m2. Furthermore, this UV irradiation had no effect on either the chondrogenic or osteogenic potential of HuMSCs. Significant effects of LAGT in HuMSCs could be detected as early as 12 h after exposure and persisted over 21 days, in a time and energy-dependent manner. This LAGT effect was maintained for more than 8 h after irradiation and required only a 10-min exposure to rAAV after UV irradiation. Finally, we show that the production of secreted TGFβ1 protein from rAAV-TGFβ1-IRES-eGFP infected to HuMSCs is highly inducible by UV irradiation. These results demonstrate that LAGT combined with rAAV is a promising procedure to facilitate gene induction in HuMSCs for human gene therapy.
AB - Deficiencies in skeletal tissue repair and regeneration lead to conditions like osteoarthritis, osteoporosis and degenerative disc disease. While no cure for these conditions is available, the use of human bone marrow derived-mesenchymal stem cells (HuMSCs) has been shown to have potential for cell-based therapy. Furthermore, recombinant adeno-associated viruses (rAAV) could be used together with HuMSCs for in vivo or ex vivo gene therapy. Unfortunately, the poor transduction efficiency of these cells remains a significant obstacle. Here, we describe the properties of ultraviolet (UV) light-activated gene transduction (LAGT) with rAAV in HuMSCs, an advance toward overcoming this limitation. Using direct fluorescent image analysis and real-time quantitative PCR to evaluate enhanced green fluorescent protein (eGFP) gene expression, we found that the optimal effects of LAGT with limited cytotoxicity occurred at a UV dose of 200 J/m2. Furthermore, this UV irradiation had no effect on either the chondrogenic or osteogenic potential of HuMSCs. Significant effects of LAGT in HuMSCs could be detected as early as 12 h after exposure and persisted over 21 days, in a time and energy-dependent manner. This LAGT effect was maintained for more than 8 h after irradiation and required only a 10-min exposure to rAAV after UV irradiation. Finally, we show that the production of secreted TGFβ1 protein from rAAV-TGFβ1-IRES-eGFP infected to HuMSCs is highly inducible by UV irradiation. These results demonstrate that LAGT combined with rAAV is a promising procedure to facilitate gene induction in HuMSCs for human gene therapy.
KW - Human bone marrow derived stem cell (HuMSCs)
KW - Light-activated gene transduction (LAGT)
KW - Recombinant adeno-associated virus (rAAV)
UR - http://www.scopus.com/inward/record.url?scp=1642514749&partnerID=8YFLogxK
U2 - 10.1038/sj.gt.3302102
DO - 10.1038/sj.gt.3302102
M3 - Article
C2 - 14681695
AN - SCOPUS:1642514749
SN - 0969-7128
VL - 11
SP - 34
EP - 41
JO - Gene therapy
JF - Gene therapy
IS - 1
ER -